Free Trial
LON:VER

Vernalis (VER) Share Price, News & Analysis

Vernalis logo
GBX 6.17 0.00 (0.00%)
(As of 10/10/2018)

About Vernalis Stock (LON:VER)

Key Stats

Today's Range
6.17
6.17
50-Day Range
6.17
6.17
52-Week Range
2.80
14
Volume
11,076 shs
Average Volume
1.22 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.

Receive VER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vernalis and its competitors with MarketBeat's FREE daily newsletter.

VER Stock News Headlines

917 Trades… Zero Losses?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
See More Headlines

VER Stock Analysis - Frequently Asked Questions

Vernalis' stock was trading at GBX 6.17 at the start of the year. Since then, VER stock has increased by 0.0% and is now trading at GBX 6.17.
View the best growth stocks for 2024 here
.

Vernalis plc (LON:VER) issued its earnings results on Tuesday, September, 12th. The company reported ($4.10) EPS for the quarter, beating the consensus estimate of ($4.50) by $0.40. The firm had revenue of $20.79 million for the quarter.

Shares of VER stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vernalis investors own include Lloyds Banking Group (LLOY), Filtronic (FTC), BP (BP), Citius Pharmaceuticals (CTXR), Eurasia Mining (EUA), Entain PLC (GVC.L) (GVC) and Herbalife (HLF).

Company Calendar

Last Earnings
9/12/2017
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
350
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (LON:VER) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners